Trial reportBJU international2026
STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.
Trial report in BJU international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesActive surveillance (AS) is the preferred approach for low-risk prostate cancer (PCa). Recent efforts have explored new biomarkers to reduce the frequency of surveillance biopsy. This study assessed Stockholm3 for predicting PCa upgrading during surveillance biopsies. MATERIALS AND
methodsThe prospective STHLM3-AS NorDCaP trial included 199 men with International Society of Urological Pathologists grade group 1 (ISUP GG 1) PCa under AS in Sweden, Denmark, and Norway (2019-2022). All men had ISUP GG 1 PCa and received a Stockholm3 test before surveillance biopsies. The primary outcome was ISUP upgrading, defined as ISUP GG 2 or higher.
resultsAt surveillance biopsy, 72 of the 199 (36%) men were upgraded. Men with upgraded PCa had higher median Stockholm3 (35; interquartile range [IQR] 26-50) than those without upgrading (23; IQR 14-34, P < 0.01). The area under the receiver operating characteristic curve (AUC) for Stockholm3 was 0.71 (95% confidence interval [CI] 0.64-0.79). For Stockholm3 ≥15, sensitivity, specificity, and negative-predictive value (NPV) were 0.93 (95% CI 0.85-0.98), 0.26 (95% CI 0.19-0.35), and 0.87 (95% CI 0.72-0.96), respectively, sparing 19% of biopsies while missing five cases (7% of upgrades), none of which were ISUP GG ≥3. At a lower threshold (≥11), sensitivity increased to 0.99 (95% CI 0.93-1.00) with lower specificity (0.11; 95% CI 0.06-0.18) and an NPV of 0.93 (95% CI 0.68-1.00). Prostate-specific antigen density ≥0.15 showed a sensitivity of 0.60 (95% CI 0.48-0.72), specificity of 0.72 (95% CI 0.63-0.80), and NPV of 0.75 (95% CI 0.66-0.83), with an AUC of 0.71 (95% CI 0.63-0.79). Prostate Imaging-Reporting and Data System score ≥3 demonstrated a sensitivity of 0.92 (95% CI 0.83-0.97), specificity of 0.33 (95% CI 0.22-0.44), and NPV of 0.84 (95% CI 0.66-0.95), with an AUC of 0.72 (95% CI 0.65-0.79).
conclusionIn men with low-risk PCa under AS, Stockholm3 may enhance risk stratification and reduce unnecessary biopsies. Prostate-specific antigen density and multiparametric magnetic resonance imaging showed comparable performance, with Stockholm3 providing a potentially practical blood-based complement in a multimodal strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.